← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › VIRAL VACCINES › Covid-19 vaccines
covid-19, virus-like particles
J07BN05
Forms & Strengths
- Injectable suspension
- 5 mcg VLP per 0.5 mL dose
Adult Dosing
- Primary series: 2 doses of 0.5 mL administered intramuscularly 21 days apart
- Booster doses: 0.5 mL administered intramuscularly at least 6 months after completion of primary series
Pediatric Dosing
- Not currently recommended or authorized for pediatric patients under 18 years of age due to lack of safety and efficacy data
Indications
- Active immunization for the prevention of COVID-19 caused by SARS-CoV-2 in adults
Mechanism of Action
- Recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus-like particles (VLPs) displaying the spike protein
- Stimulates neutralizing antibody production and cellular immune responses against SARS-CoV-2
Contraindications
- History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine
Adverse Reactions
- Injection site pain, tenderness, redness, and swelling
- Systemic effects including fatigue, headache, myalgia, arthralgia, chills, and fever
- Rare reports of lymphadenopathy and hypersensitivity reactions
Drug Interactions
- Immunosuppressive therapies may reduce the immune response to the vaccine
- Do not mix with any other vaccines or medicinal products in the same syringe
Curated Content: Needs Vetting Before Put to Clinical Use